Cima Sciences is proud to exhibit at the 2025 AASLD The Liver Meeting in Washington, D.C. Along with Rubió Metabolomics, we are excited to connect with existing and new clients interested in the most comprehensive detection of all treatable stages of MASLD.
Come visit us at Booth# 761 to further discuss using OWLiver in your practice or clinical studies.
Additionally, we will presenting and co-presenting some exciting data within the Poster sessions. It is a great opportunity to meet with the presenters. Check out the poster presentations below:
-Maximizing the Diagnostic Yield of Non-Invasive Tests: Simultaneous Optimization of Key Performance Metrics for Fibrotic Liver Disease with a FIB-4 and MASEF (OWLiver) Strategy. Publication Number: 2077. Presentation date: Saturday 8th.
-Saroglitazar treatment reduced severity of MASLD phenotypes by lipidomic-based test OWLiver in subjects with MASLD in a 16-week phase 2 trial. Publication number: 4020. Presentation Date: Monday 10th. Poster of distinction.